Updated results from a phase II study of mini-hyper-CVD (mini-HCVD) plus inotuzumab ozogamicin (INO), with or without blinatumomab (Blina), in older adults with newly diagnosed Philadelphia chromosome (Ph)-negative B-cell acute lymphoblastic leukemia (ALL).

被引：0
|
作者：
Macaron, Walid
Kantarjian, Hagop M.
Short, Nicholas James
Ravandi, Farhad
Jain, Nitin
Kadia, Tapan M.
Haddad, Fadi
Valero, Yesid Alvarado
Daver, Naval Guastad
Borthakur, Gautam
Dinardo, Courtney Denton
Konopleva, Marina
Wierda, William G.
Jacob, Jovitta
Roy, Edith
Loiselle, Christopher
Milton, Anna
Rivera, Juan
Garris, Rebecca
Jabbour, Elias
机构：
[1] MD Anderson Canc Ctr, Houston, TX USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7011
引用
收藏
页数：1
相关论文
共 50 条
  • [31] The Addition of Inotuzumab Ozogamicin to Hyper-CVAD Plus Blinatumomab Further Improves Outcomes in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia: Updated Results from a Phase II Study
    Short, Nicholas
    Jabbour, Elias
    Ravandi, Farhad
    Yilmaz, Musa
    Kadia, Tapan M.
    Thompson, Philip A.
    Huang, Xuelin
    Konopleva, Marina
    Ferrajoli, Alessandra
    Jain, Nitin
    Sasaki, Koji
    Macaron, Walid
    Alvarado, Yesid
    Borthakur, Gautam
    DiNardo, Courtney D.
    Ohanian, Maro
    Kornblau, Steven M.
    Zhao, Min
    Kwari, Monica
    Thankachan, Jennifer
    Loiselle, Christopher
    Delumpa, Ricardo
    Garris, Rebecca
    Kantarjian, Hagop
    BLOOD, 2022, 140 : 8966 - 8968
  • [32] Hyper-CVAD and Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: Results from a Phase II Study
    Short, Nicholas J.
    Kantarjian, Hagop M.
    Ravandi, Farhad
    Huang, Xuelin
    Ferrajoli, Alessandra
    Kadia, Tapan M.
    Thompson, Philip A.
    Alvarado, Yesid
    Jain, Nitin
    Yilmaz, Musa
    Khoury, Joseph D.
    Jorgensen, Jeffrey L.
    Wang, Sa A.
    Kornblau, Steven M.
    Konopleva, Marina
    Garcia-Manero, Guillermo
    Schroeder, Heather M.
    Kwari, Monica
    Paul, Shilpa
    Nwakanme, Benjamin
    Loiselle, Christopher
    Garris, Rebecca
    O'Brien, Susan M.
    Jabbour, Elias
    BLOOD, 2020, 136
  • [33] Inotuzumab Ozogamicin plus Blinatumumab plus /- Rituximab plus Mini-Hcvd Shows Improved Tolerability with Similar Efficacy Compared to E1910 in Treatment of Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia in Older Adults
    Scott, Jordan
    Poblete, Samantha
    Vega, Jared
    Przespolewski, Amanda C.
    Thompson, James E.
    Griffiths, Elizabeth A.
    Sung, Pamela Jeannette
    Green, Steven
    Yu, Han
    Shenal, Michael
    Przespolewski, Eugene
    Wang, Eunice S.
    Baron, Jeffrey
    BLOOD, 2023, 142
  • [34] Mini-hyper-CVD with venetoclax (Ven) for patients with relapsed/refractory (R/R) Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL): A phase II study
    Zoghbi, Marianne
    Jabbour, Elias
    Haddad, Fadi
    Short, Nicholas James
    Senapati, Jayastu
    Macaron, Walid
    Nasnas, Cedric Christophe
    Nasr, Lewis Fady
    Pemmaraju, Naveen
    Jain, Nitin
    Wierda, William G.
    Borthakur, Gautam
    Bravo, Guillermo Montalban
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Kadia, Tapan M.
    Chien, Kelly Sharon
    Thankachan, Jennifer
    Garris, Rebecca
    Kantarjian, Hagop M.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [35] Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial (vol 10, pg e433, 2023)
    Jabbour, E.
    Short, N. J.
    Senapati, J.
    LANCET HAEMATOLOGY, 2023, 10 (07): : E490 - E490
  • [36] Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia
    Jabbour, Elias
    Sasaki, Koji
    Short, Nicholas J.
    Ravandi, Farhad
    Huang, Xuelin
    Khoury, Joseph D.
    Kanagal-Shamanna, Rashmi
    Jorgensen, Jeffrey
    Khouri, Issa F.
    Kebriaei, Partow
    Jain, Nitin
    Alvarado, Yesid
    Kadia, Tapan M.
    Paul, Shilpa
    Garcia-Manero, Guillermo
    Dabaja, Bouthaina S.
    Burger, Jan A.
    DiNardo, Courtney D.
    Daver, Naval A.
    Montalban-Bravo, Guillermo
    Yilmaz, Musa
    Ohanian, Maro
    Ferrajoli, Alessandra
    Jacob, Jovitta
    Rostykus, Meagan
    Garris, Rebecca
    O'Brien, Susan
    Kantarjian, Hagop M.
    CANCER, 2021, 127 (12) : 2025 - 2038
  • [37] Updated results of a phase I/II study of inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-hyper-CVD) as frontline therapy for older patients with acute lymphoblastic leukemia.
    Short, Nicholas James
    Kantarjian, Hagop M.
    O'Brien, Susan Mary
    Ravandi, Farhad
    Thomas, Deborah A.
    Garcia-Manero, Guillermo
    Daver, Naval Guastad
    Borthakur, Gautam
    Jain, Nitin
    Konopleva, Marina
    Sasaki, Koji
    Pemmaraju, Naveen
    Alvarado, Yesid
    Jacob, Jovitta
    Garris, Rebecca
    Thompson, Philip A.
    Cortes, Jorge E.
    Jabbour, Elias
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [38] INOTUZUMAB OZOGAMICIN IN COMBINATION WITH LOW-INTENSITY CHEMOTHERAPY (MINI-HYPER-CVD) AS FRONTLINE THERAPY FOR OLDER PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA: UPDATED RESULTS FROM A PHASE I/II TRIAL
    Short, N.
    Kantarjian, H.
    O'Brien, S.
    Ravandi, F.
    Thomas, D.
    Garcia-Manero, G.
    Daver, N.
    Borthakur, G.
    Jain, N.
    Konopleva, M.
    Sasaki, K.
    Pemmaraju, N.
    Alvarado, Y.
    Jacob, J.
    Garris, R.
    Thompson, P.
    Cortes, J.
    Jabbour, E.
    HAEMATOLOGICA, 2017, 102 : 34 - 35
  • [39] Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia A Phase 2 Clinical Trial
    Jabbour, Elias
    Ravandi, Farhad
    Kebriaei, Partow
    Huang, Xuelin
    Short, Nicholas J.
    Thomas, Deborah
    Sasaki, Koji
    Rytting, Michael
    Jain, Nitin
    Konopleva, Marina
    Garcia-Manero, Guillermo
    Champlin, Richard
    Marin, David
    Kadia, Tapan
    Cortes, Jorge
    Estrov, Zeev
    Takahashi, Koichi
    Patel, Yogin
    Khouri, Maria R.
    Jacob, Jovitta
    Garris, Rebecca
    O'Brien, Susan
    Kantarjian, Hagop
    JAMA ONCOLOGY, 2018, 4 (02) : 230 - 234
  • [40] Roleof Allogeneic Stem Cell Transplant (ASCT) in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blina): Results from a Phase 2 Study
    Rafei, Hind
    Kantarjian, Hagop M.
    Sasaki, Koji
    Short, Nicholas J.
    Ravandi, Farhad
    Huang, Xuelin
    Khoury, Joseph D.
    Wang, Sa A.
    Jorgensen, Jeffrey L.
    Khouri, Issa F.
    Kebriaei, Partow
    Champlin, Richard E.
    Jain, Nitin
    Dabaja, Bouthaina S.
    Issa, Ghayas C.
    Pemmaraju, Naveen
    Kadia, Tapan M.
    Paul, Shilpa
    Jammal, Nadya
    Garcia-Manero, Guillermo
    Wierda, William G.
    DiNardo, Courtney D.
    Daver, Naval
    Montalban-Bravo, Guillermo
    Khouri, Rita
    Nasnas, Patrice
    Thompson, Philip A.
    Jacob, Jovitta
    Rostykus, Meagan
    Garris, Rebecca
    Konopleva, Marina
    O'Brien, Susan M.
    Jabbour, Elias
    BLOOD, 2020, 136
12345